News
Feed
Events
Feed
News
+ Events
Feed

Zeige 1 - 42 von 42 Ergebnissen

31 Oktober 2024

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Announces Appointment of Konstantin Petropoulos as Chief Executive Office
9 September 2024

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals will present data at 6th Inflammasome Therapeutics Summit demonstrating the potential of ASOs to target the expression of NLRP3
4 September 2024

Secarna Pharmaceuticals GmbH & Co. KG

Secarna establishes Scientific Advisory Board with leading oncology experts Prof. Dr. Eggermont and Prof. Dr. Zippelius
22 Juli 2024

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals publishes new data in Nucleic Acid Therapeutics showcasing strategies to detect and prevent immunostimulatory potential of LNA-modified ASOs
28 Mai 2024

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics
20 März 2024

Secarna Pharmaceuticals GmbH & Co. KG

Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies
3 November 2023

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals presents data at SITC demonstrating the potential of antisense oligonucleotides in targeting NRP1
25 Oktober 2023

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals presents data at OTS showcasing unique characteristics and factors with a role in the activity and side effect profile of LNA-modified ASOs
17 Oktober 2023

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals to present two posters showcasing the innovation potential of the LNAplus platform at the 19th Annual Meeting of the Oligonucleotide Therapeutic Society
6 Juli 2023

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals publishes new preclinical data in The Journal of Immunology demonstrating potent therapeutic activity of LNAplus™ ASO targeting NLRP3 in debilitating autoinflammatory diseases
5 Juni 2023

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals announces publication of new preclinical data showing durable antitumor activity of LNAplus™-based ASOs that both stimulate the innate immune system and suppress PD-L1 expressi
27 März 2023

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals and SciNeuro Pharmaceuticals enter into research and option agreement in the field of CNS diseases
31 Mai 2022

Secarna Pharmaceuticals GmbH & Co. KG

First subject dosed in Lipigon’s phase I clinical study with antisense oligonucleotide candidate derived from Secarna Pharmaceutical’s LNAplus™ technology platform
12 April 2022

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals' strategic partner Evotec achieves programme designation in neuroscience collaboration with Bristol Myers Squibb
22 Februar 2022

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals' partner Denali Therapeutics exercises option for LNAplusTM antisense oligonucleotide development program in neurodegeneration
10 November 2021

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals and Achilles Therapeutics sign research, option and license agreement to develop optimized T cell therapies
26 Oktober 2021

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals and Denali Therapeutics expand strategic partnership for the discovery and development of novel ASO therapeutics in the field of CNS diseases
25 Oktober 2021

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals has initiated a transnational scientific consortium to identify new biomarkers for personalized cancer immunotherapy with ASOs
5 Oktober 2021

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals announces publication of new preclinical data showing strong potential of LNAplus(TM)-based ASOs to effectively treat diabetic kidney disease
2 September 2021

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals GmbH & Co. KG: Secarna Pharmaceuticals and Evotec expand strategic partnership in the field of antisense drug discovery
5 August 2021

Secarna Pharmaceuticals GmbH & Co. KG

Secarna publishes new scientific insights in Nucleic Acid Therapeutics on fundamental determinants of antisense oligonucleotide activity
4 Februar 2021

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals appoints Alexander Gebauer, MD, PhD as CEO and Managing Director
20 Januar 2021

Secarna Pharmaceuticals GmbH & Co. KG

Data published in Molecular Diagnostics & Therapy demonstrate how Secarna's powerful bioinformatics generate improved LNA-modified antisense oligonucleotide therapies
19 Januar 2021

Secarna Pharmaceuticals GmbH & Co. KG

Antisense oligonucleotide candidate derived from Secarna Pharmaceuticals' LNAplusTM platform has entered pre-clinical safety trials for the treatment of elevated blood lipids
8 Dezember 2020

Secarna Pharmaceuticals GmbH & Co. KG

Data published in Cancer Research show Secarna Pharmaceuticals' LNAplus(TM) ASOs targeting metadherin significantly slow progression and metastasis of colorectal and lung cancers in vivo
13 Oktober 2020

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals and Denali Therapeutics enter into research and option agreement to develop novel antisense therapies in the field of neurodegenerative diseases
5 August 2020

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals und Evotec gehen strategische Partnerschaft im Bereich Antisense-Therapie ein
28 April 2020

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals enters into cooperation with Guangzhou's Sun Yat-sen University to develop a treatment for SARS-CoV-2 viral infections
26 März 2020

Secarna Pharmaceuticals GmbH & Co. KG

Newly published data in Cancer Immunology, Immunotherapy support the potential of Secarna Pharmaceuticals' LNA-modified ASOs to effectively block important immunosuppressive pathway
23 März 2020

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals announces the acquisition of LNAplusTM based antisense drug candidates by Lipigon Pharmaceuticals
11 November 2019

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals successfully completes financing round
7 November 2019

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals to Attend International Partnering and Investor Conferences in November
10 September 2019

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals enters into oncology research agreement with global top 10 pharmaceutical company
6 Mai 2019

Secarna Pharmaceuticals GmbH & Co. KG

Publications of Secarna Pharmaceuticals' immuno-oncology data in peer-reviewed scientific journals support potential of LNAplusTM antisense oligonucleotide platform for discovering novel cancer therapies
5 November 2018

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals and MetP Pharma enter into a co-development agreement for transnasally delivered antisense oligonucleotide-based CNS therapeutics
17 Oktober 2018

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals to attend BIO-Europe(R) 2018 - 24th Annual International Partnering Conference
10 Oktober 2018

Secarna Pharmaceuticals GmbH & Co. KG

As partner in the INAT consortium Secarna Pharmaceuticals receives Horizon 2020 grant to develop inhaled nanocarriers with antisense therapy as a novel therapeutic approach for lung fibrosis
26 September 2018

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals to hold poster presentations on two development programs at the 14th Annual Meeting of the Oligonucleotide Therapeutics Society
19 September 2018

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals successfully hosted Inaugural Industry Expert Meeting and Networking Event for the Oligonucleotide Therapeutics Society (OTS) in Munich
5 September 2018

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals and Firebrand Therapeutics enter into co-development agreement for novel cancer therapies
30 August 2018

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals announces poster presentation on targeting RORgt with an innovative antisense oligonucleotides approach at the European Congress of Immunology
4 Juni 2018

Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals stellt LNAplusTM vor, die unternehmenseigene, maßgeschneiderte Plattform für die Forschung und Entwicklung von Antisense-Oligonukleotid-(ASO)-Arzneimittelkandidaten der dritten Generation